1. Academic Validation
  2. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

  • Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357.
Sonia Brun 1 Eloïne Bestion 1 2 Eric Raymond 1 3 Firas Bassissi 1 Zuzana Macek Jilkova 4 5 6 Soraya Mezouar 1 Madani Rachid 1 Marie Novello 1 Jennifer Tracz 1 Ahmed Hamaï 7 8 Gilles Lalmanach 9 10 Lise Vanderlynden 9 10 Raphael Legouffe 11 Jonathan Stauber 12 Thomas Schubert 13 Maximilian G Plach 13 Jérôme Courcambeck 1 Cyrille Drouot 1 Guillaume Jacquemot 1 Cindy Serdjebi 1 Gael Roth 4 5 6 Jean-Pierre Baudoin 2 Christelle Ansaldi 1 Thomas Decaens 4 5 6 Philippe Halfon 1
Affiliations

Affiliations

  • 1 Genoscience Pharma, Marseille, France.
  • 2 Aix-Marseille Univ, MEPHI, APHM, IRD, IHU Méditerranée Infection, Marseille, France.
  • 3 Medical Oncology, Paris Saint-Joseph Hospital, Paris, France.
  • 4 Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France.
  • 5 University of Grenoble Alpes, Faculté De Médecine, France.
  • 6 Clinique Universitaire d'Hépato-gastroentérologie, Pôle Digidune, Chu Grenoble, France.
  • 7 Institut Necker-Enfants Malades, Inserm U1151-CNRS UMR, Paris, France.
  • 8 University of Paris Descartes-Sorbonne Paris Cité, Paris, France.
  • 9 Inserm, UMR1100, Centre d'Etude Des Pathologies Respiratoires, Equipe "Mécanismes Protéolytiques Dans l'Inflammation", Tours, France.
  • 10 University of Tours, Tours, France.
  • 11 ImaBiotech, Loos, France.
  • 12 ImaBiotech, Billerica, USA.
  • 13 2Bind GmbH, Regensburg, Germany.
Abstract

Hepatocellular carcinoma is the most frequent primary liver Cancer. Macroautophagy/Autophagy inhibitors have been extensively studied in Cancer but, to date, none has reached efficacy in clinical trials. In this study, we demonstrated that GNS561, a new Autophagy inhibitor, whose Anticancer activity was previously linked to lysosomal cell death, displayed high liver tropism and potent antitumor activity against a panel of human Cancer cell lines and in two hepatocellular carcinoma in vivo models. We showed that due to its lysosomotropic properties, GNS561 could reach and specifically inhibited its enzyme target, PPT1 (palmitoyl-protein thioesterase 1), resulting in lysosomal unbound Zn2+ accumulation, impairment of Cathepsin activity, blockage of autophagic flux, altered location of mTOR (mechanistic target of rapamycin kinase), lysosomal membrane permeabilization, Caspase activation and cell death. Accordingly, GNS561, for which a global phase 1b clinical trial in liver cancers was just successfully achieved, represents a promising new drug candidate and a hopeful therapeutic strategy in Cancer treatment.Abbreviations: ANXA5:annexin A5; ATCC: American type culture collection; BafA1: bafilomycin A1; BSA: bovine serum albumin; CASP3: Caspase 3; CASP7: Caspase 7; CASP8: Caspase 8; CCND1: cyclin D1; CTSB: Cathepsin B; CTSD: Cathepsin D; CTSL: Cathepsin L; CQ: chloroquine; iCCA: intrahepatic cholangiocarcinoma; DEN: diethylnitrosamine; DMEM: Dulbelcco's modified Eagle medium; FBS: fetal bovine serum; FITC: fluorescein isothiocyanate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; HDSF: hexadecylsulfonylfluoride; IC50: mean half-maximal inhibitory concentration; LAMP: lysosomal associated membrane protein; LC3-II: phosphatidylethanolamine-conjugated form of MAP1LC3; LMP: lysosomal membrane permeabilization; MALDI: matrix assisted laser desorption ionization; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MKI67: marker of proliferation Ki-67; MTOR: mechanistic target of rapamycin kinase; MRI: magnetic resonance imaging; NH4Cl: ammonium chloride; NtBuHA: N-tert-butylhydroxylamine; PARP: poly(ADP-ribose) polymerase; PBS: phosphate-buffered saline; PPT1: palmitoyl-protein thioesterase 1; SD: standard deviation; SEM: standard error mean; vs, versus; Zn2+: zinc ion; Z-Phe: Z-Phe-Tyt(tBu)-diazomethylketone; Z-VAD-FMK: carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone.

Keywords

Antitumor; PPT1; autophagy; liver cancer; lysosome; mtor.

Figures
Products